ImpRoving hEalth behaviourS for LIfe After ENdometrial CancEr Trial (NCT06038032)
The RESILIENCE Trial: Using a Multimodal and Digital Intervention to Optimize Waist Circumference, Body Composition, and Cardiometabolic Health in Endometrial Cancer Survivors.
🩺 Plain-English Summary (8th-Grade Level)
RESILIENCE is 24-week randomized controlled trial that assesses the efficacy of a digital wellness platform, combined with online support from healthcare professionals, to enhance waist circumference and other vital health outcomes in endometrial cancer survivors.
Who can join: Review the eligibility criteria below.
Location: University of Alberta — Edmonton, Alberta
Age range: 18 Years
🧪 Interventions in This Study
- Digital wellness platform (BEHAVIORAL)
- Online healthcare professional support (BEHAVIORAL)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (2 Sites)
- University of Alberta — Edmonton, Alberta
- University of Toronto — Toronto,
📞 Contact the Study Coordinator
Phone: (780) 492-1151
Email: resilience.trial@ualberta.ca
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Endometrial Cancer
- Selective Surgical Staging for the Treatment of Endometrial Cancer Based on Intraoperative Consultation — Lexington, Kentucky
- Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005) — Mobile, Alabama
- Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer — Houston, Texas
- A Study of Giredestrant in Participants With Grade 1 Endometrial Cancer — Little Rock, Arkansas
- Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line — Garran,
- Activity and Cancer Survivorship Exercise Pilot — Iowa City, Iowa
Explore by condition: All Endometrial Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.